Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling of whole tumor biopsies of mPDAC patients in Optimize-1

ABSTRACT: Transcriptomic profiling of whole tumor biopsies of mPDAC patients in Optimize-1

PROVIDER: PRJNA1232839 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic profiling of whole tumor biopsies of mPDAC patients in Optimize-1

Project description:This dataset was generated to study the transcriptomic alterations in tumor tissue of mPDAC patients from the Optimize-1 (A-20-1013-C-03), with available RNA-seq data and their associations with clinical efficacy endpoints from the 18-months follow up dataset.

2025-08-18 | GSE291331 | GEO

Dual tumor and normal biopsies from various cancer patients

Project description:Dual tumor and normal biopsies from various cancer patients

| PRJNA713292 | ENA

Tumor biopsies from 71 untreated patients with mantle cell lymphoma

Project description:The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Keywords: lymphochip; MCL; untreated Tumor biopsies from 71 untreated patients with mantle cell lymphoma

2010-05-23 | E-GEOD-10793 | biostudies-arrayexpress

Proteomic characterization of human hepatocellular carcinoma (HCC) tumor biopsies

Project description:We analyzed the proteome of tumor and matched non-tumor biopsies from 51 treatment-naive Hepatocellular carcinoma (HCC) patients by DIA (SWATH). Thereby we aim to find subgroups of patients characterized by specific pathway activation. Furthermore, we aim to find novel factors involved in HCC development and novel biomarkers.

2022-03-14 | PXD025705 | Pride

Phospho-proteomic characterization of human hepatocellular carcinoma (HCC) tumor biopsies

Project description:We analyzed the phospho-proteome of tumor and matched non-tumor biopsies from 51 treatment-naive Hepatocellular carcinoma (HCC) patients by label-free DDA. Thereby we aim to find subgroups of patients characterized by specific pathway activation. Furthermore, we aim to find novel factors involved in HCC development and novel biomarkers.

2022-03-14 | PXD025836 | Pride

Single-cell transcriptomic profiles of metastatic lesion biopsies and PBMCs from M1-stage prostate cancer patients

Project description:This dataset contains single-cell RNA sequencing (scRNA-seq) data generated from patients with M1-stage metastatic prostate cancer, comprising two complementary sample types: metastatic lesion biopsies from five patients and peripheral blood mononuclear cells (PBMCs) from seven patients. Together, these datasets support integrated profiling of the metastatic tumor microenvironment and the systemic immune landscape. The processed data include log-normalized gene expression matrices and detailed cell-level metadata, enabling analyses of tumor–immune interactions, circulating immune phenotypes, and molecular features associated with metastatic disease progression. A related bulk RNA-seq dataset from primary tumor biopsies is available (see Related Series: GSE297742), providing opportunities for comparative transcriptomic analyses between primary and metastatic disease states.

2025-11-19 | GSE297652 | GEO

Paired human colon and tumor biopsies

Project description:Paired human colon and tumor biopsies

| PRJNA808084 | ENA

Transcriptomic analyzes of bone biopsies from patients with renal osteodystrophy (ROD)

Project description:RNAseq of bone biopsies of healthy patients and patients with renal osteodystrophy.

2023-06-07 | GSE194056 | GEO

Phosphoproteomics scaled-down to tumor biopsy level. Part 2: biopsies

Project description:Mass spectrometry-based phosphoproteomics of tumor tissue or cell line lysates provides insight in aberrantly activated signaling pathways and potential drug targets. For improved understanding of the individual patient’s tumor biology, analysis of the phosphoproteome should be feasible and reproducible using tumor needle biopsies. We hereto scaled down a pTyr-phosphopeptide enrichment protocol to biopsy-level protein input and show its performance using colorectal cancer (CRC) cell line and needle biopsies from patients. In this study, the feasibility of label-free pTyr-phosphoproteomics at the biopsy level is demonstrated. Unsupervised cluster analysis shows that this approach can identify patient-specific profiles, which will improve our understanding of individual tumor biology and may enable future pTyr-phosphoproteomics-based TKI treatment selection.

2019-10-28 | PXD003814 | Pride

Gene expression profiles of tumor-positive sentinel lymph node biopsies from cutaneous melanoma patients

Project description:Sentinel lymph node, the first node draining the primary tumor, is a key component of tumor microenvironment promoting immune tolerance. In melanoma, sentinel node is one of the most important prognostic factors and the most frequent site of regional metastasis. To unravel the immunomodulatory pathways that are triggered by melanoma cells in the draining node that allow tumor spreading, transcriptional profiles associated to disease progression were analyzed in archival sentinel node biopsies (SNB). Gene expression profiles of melanoma-positive and negative SNB selected to maximize the differences in terms of disease stage and course, revealed subgroups correlating with regional node involvement and disease progression within positive biopsies. Transcriptional profiles revealed that genes showing differential expression between tumor-positive SNB with/without disease progression were mainly related to inflammatory response and that were mostly down regulated in patients with poor prognosis. TNFRSF8 encoding CD30 showing up regulation in SNB from patients with progressing disease displayed higher expression by immunohistochemical staining compared to SNB from non progressing patients. Subpopulations of CD30 positive CD4/CD8 double negative and CD4 Foxp3/PD-1 CD147 positive T cells were identified by flow cytometry analysis in metastatic nodes, suggesting a potential role of regulatory and tolerogenic T cells in melanoma progression.

2013-08-01 | GSE39945 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data